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Alzheimer’s disease is the most common form of dementia in the elderly and is a progressive neurodegenerative disorder
characterised by a decline in cognitive function and also profound alterations in mood and behaviour. The pathology of the
disease is characterised by the presence of extracellular amyloid peptide deposits and intracellular neuroﬁbrillary tangles in the
brain. Although many hypotheses have been put forward for the aetiology of the disease, increased inﬂammation and oxidative
stressappearkeytobefeaturescontributingtothepathology.Theomega-3polyunsaturatedfats,eicosapentaenoicacid(EPA),and
docosahexaenoic acid (DHA) have well-characterised eﬀects on inﬂammation and may have neuroprotective eﬀects in a number
of neurodegenerative conditions including Alzheimer’s disease. The aims of this paper are to review the neuroprotective eﬀects of
EPA and DHA in Alzheimer’s disease, with special emphasis on their role in modulating oxidative stress and inﬂammation and
also examine their potential as therapeutic agents.
1.Introduction
Alzheimer’s disease (AD) is the most common form of
dementia in the elderly. It is a progressive neurodegenerative
disorder characterised by a decline in cognitive function and
also profound alterations in mood and behaviour [1]. The
pathology of the disease is characterised by the presence of
extracellular amyloid peptide deposits, soluble amyloid β-
protein and hyperphosphorylated tau protein leading to the
formationofintracellularneuroﬁbrillarytanglesinthebrain.
The aetiology and pathogenesis of the disease are currently
poorly understood, and the present management is to a
large extent symptomatic and focused on ameliorating the
cognitive deﬁcits [2]. However, although many hypotheses
have been put forward for the aetiology of the disease,
increasedinﬂammation [3]andoxidative stress[4]ap peart o
be key features contributing to the pathology of the disease.
The omega-3 polyunsaturated fatty acids (PUFA), eicos-
apentaenoic acid (EPA), and docosahexaenoic acid (DHA)
have well-characterised eﬀects on inﬂammation [5]a n d
may have neuroprotective eﬀe c t si nan u m b e ro fn e u r o d e -
generative conditions including AD [6]. The purpose of
this paper is to review the neuroprotective eﬀects of EPA
and DHA in AD with emphasis on their potential for
modulating amyloidosis and the increased oxidative stress
and inﬂammation seen with AD and explore their potential
application as therapeutic agents.
2. Amyloid β-Peptide
A major hallmark of AD is the overproduction of amyloid β-
peptide (Aβ), which results in the formation of plaques. Aβ
peptides are produced by successive proteolysis of amyloid
precursor protein (APP) by β-site APP-cleaving enzyme-
1( B A C E 1 )f o l l o w e db yγ-secretase [7–9]. This cleavage is
imprecise and produces Aβ variants, which include those
ending at residues 40 (Aβ40)a n d4 2( A β42)[ 10]. The Aβ42
is deposited earliest and most abundantly in plaques [11].
Aβ has been shown to induce lipid peroxidation in brain cell
membranes and increase production of the lipid peroxida-
tion products 4-hydroxynonenal and acrolein, and this may
in part account for neurodegeneration in AD brain [12].2 International Journal of Alzheimer’s Disease
Several groups have investigated the role of DHA-
enriched diets in animal models of AD and amyloidosis.
In a series of studies Hashimoto and colleagues pretreated
rats with DHA (300mg/kg per day for 12 weeks) before
an infusion of Aβ1−40 [13–15]. DHA had a signiﬁcantly
protective eﬀect against the decrease in learning ability and
reduced the oxidative stress induced by the Aβ infusion
in the cerebral cortex and hippocampus. Pretreatment
with DHA also prevented Aβ-induced impairment of an
avoidance ability-related memory function. This group also
investigated the protective eﬀects of the DHA pretreatment
before Aβ infusion on synaptosomal membranes properties.
DHA content signiﬁcantly increased along with both lateral
and rotational membrane ﬂuidity, whereas the cholesterol to
phospholipid molar ratio and lipid peroxidation decreased.
Elevated cholesterol increases Aβ levels in both in vitro
and in vivo models of AD, and the generation, accumulation,
and clearance of Aβ are regulated by cholesterol [16–
18], suggesting an important role for cholesterol in the
pathogenesis of AD. Indeed, cholesterol is now a recognized
risk factor in the pathogenesis of AD [18]. Furthermore,
Aβ generation may be determined by dynamic interactions
of APP with lipid rafts, since APP inside rafts undergoes
cleavage by β-secretase, whereas APP outside rafts undergoes
cleavage by α-secretase [19]. Lipid rafts are lateral assemblies
of sphingolipids and cholesterol within the membrane [20],
and it has been suggested that age-related increases in
cholesterol in lipid rafts provides a cooperative environment
for accumulation of Aβ in plasma membranes [21]. It is
therefore of interest to note that omega-3 PUFAs reduce the
level of cholesterol in neuronal membranes [22], moreover
cholesterol has a low aﬃnity for DHA-containing phospho-
lipids and therefore alterations in the level of membrane
DHA will aﬀect the formation of lipid rafts [23, 24]. It may
be that the eﬀects of DHA on cholesterol levels and lipid
raft formation represent an important, but as-yet relatively
unexplored, neuroprotective mechanism.
Recent work by Green and coworkers has shown that
DHA reduces the levels of soluble and intraneuronal Aβ
and somatodendritic tau protein in the 3xTg AD mouse
model [25]. The reduction was attributed to a decrease in the
steady-state levels of presenilin 1. Importantly, when DHA
was combined with either arachidonic or docosapentaenoic
acids(bothomega-6PUFAs)theeﬃcacyofDHAdiminished
over time, with the eﬀects lost by 9 months. However, the
additional presence of docosapentaenoic acid in the diet
reduced levels of early-stage phospho-tau epitopes, which
correlated with the positive outcome of a reduction in phos-
phorylated (activated) c-Jun N-terminal kinase, a putative
tau kinase. It may be that the interrelationship between
omega-6 and omega-3 PUFAs is a further important but
neglected area of research. DHA has also been shown to sig-
niﬁcantly increase levels of the sorting protein LR11/SorLA
in primary rat neurons, aged nontransgenic mice, and
aged DHA-depleted APPsw AD mice [26]. This increase
reduces the traﬃcking of the amyloid precursor protein to
secretases involved in the β-amyloidogenic pathway, and
reduced LR11/SorLA expression is strongly correlated with
AD neuropathology [27].
DHA also attenuates Aβ secretion in cytokine-stressed
human neural cells, and this is accompanied by formation
of neuroprotectin D1 [28]. 10,17S-docosatriene, also known
as neuroprotectin D1, is a metabolite of DHA, which
has been shown to have potent anti-inﬂammatory and
neuroprotective eﬀects in neural systems [29]a n ds t r o k e
[30]. DHA and neuroprotectin D1 were reduced in the
hippocampus cornu ammonis region 1 (CA1) of AD brains,
but not in the thalamus or occipital lobes of the same brains.
Furthermore, expression of cytosolic phospholipase A2 and
15-lipoxygenase, which are key enzymes in neuroprotectin
D1 biosynthesis, was altered in AD hippocampus. Neuro-
protectin D1 also repressed the Aβ42-triggered activation of
proinﬂammatory genes and upregulated the antiapoptotic
genes encoding Bcl-2, Bcl-xl, and Bﬂ-1(A1). The soluble
amyloid precursor protein-alpha (APP-α) stimulated the
biosynthesis of neuroprotectin D1 from DHA. These results
suggest that the beneﬁcial eﬀects of DHA may in part also
be mediated via the production of neuroprotectin D1, which
induces anti-apoptotic and neuroprotective gene expression
and consequently suppresses Aβ42-induced neurotoxicity.
Positive eﬀects of DHA treatment have not however been
universally reported and a recent study by Arendash and
co-workers found that a high omega-3 PUFA diet provided
no signiﬁcant beneﬁt in terms of decreasing the levels
of soluble/insoluble hippocampal Aβ levels or improving
cognitive performance in neither amyloid precursor protein
(APP)-sw and PS1 double transgenic or wild-type mice [31].
The authors did ﬁnd that higher cortical levels of omega-
6 PUFA in both the transgenic and wild type mice were
associated with impaired cognitive function, as measured
by the radial arm water maze and Morris water maze tests.
It may be that if DHA is acting via a reduction in the
steady-state levels of presenilin 1, as suggested by Green
and co-workers [25], the overexpression of presenilin 1 in
the transgenic mouse model used in this study overwhelms
the capacity of DHA, and therefore this model may not
accurately reﬂect the potential eﬀects in patients, especially
those aﬀected by sporadic AD. Furthermore, the omega-
3 PUFA experimental diet contained high levels of EPA,
which may have antagonised the eﬀects of DHA (4.7%
EPA and 5.7% DHA expressed as % total fat) by for
example competing for enzymes in the neuroprotectin D1
biosynthetic pathway.
An additional mechanism leading to a decrease in Aβ
levels has been suggested by a study investigating the eﬀect
of omega-3 PUFA enrichment on gene expression in aged
rats [32]. In this study, there was a 10-fold increase in
transthyretin transcription following treatment, and since
transthyretin is an Aβ protein scavenger [33], the authors
concludedthatthe omega-3PUFA-inducedexpression could
potentially prevent amyloid aggregate formation. Indeed
Serot and co-workers found an inverse relationship between
transthyretin levels in cerebrospinal ﬂuid and the severity of
dementia in AD patients [34].
Several lines of evidence indicate that alterations in
retinoid signalling lead to Aβ accumulation. For example,
vitamin A deprivation results in deposition of Aβ in the
cerebral blood vessels and downregulation of the retinoicInternational Journal of Alzheimer’s Disease 3
acid receptor, RARα in adult rat forebrain [35], and
APP/presenilin 1 double mutant transgenic mice treated for
8 weeks with retinoic acid show signiﬁcantly decreased Aβ
deposition, tau phosphorylation, activation of microglia and
astrocytes, attenuated neuronal degeneration and improved
spatial memory compared to controls [36]. Retinoic acid
regulates gene expression via its nuclear receptors: the
retinoic acid receptors (RARs) and retinoid X receptors
(RXRs) [37]. DHA and EPA have been reported to act as
endogenous ligands of RXRs [38–40], and omega-3 PUFA
supplementation has recently been shown to reverse age-
related decreases in the levels of RARα,R X R α,a n dR X R β
in the aged rat forebrain [41]. It may be that omega-3
PUFAs are acting at a fundamental level of cell regulation by
controlling gene expression via these receptors.
Omega-3 PUFA may also be acting at proliferator-
activated receptors (PPARs), in particular PPARγ.P P A R s
are involved in the control of the expression of a variety of
genes involved in lipid energy metabolism and inﬂammation
[42]. In vitro Aβ uptake and clearance from glial and
neuronal medium is increased by PPARγ [43]. In models
of AD PPARγ agonists reduce BACE1 transcription and
expression in APP transgenic mice [44, 45], PPARγ agonist
and ibuprofen treatment reduce the expression of BACE1
and Aβ42 amyloid deposits in the hippocampus and cortex of
APPV717I mice [46], and PPARγ agonists protect neurons
against Aβ-induced mitochondrial damage, apoptosis, and
oxidative stress [47]. Furthermore, treatment with PPARγ
agonistssigniﬁcantlyimprovesmeasuresofcognitioninmild
AD and mild cognitively impaired subjects compared to a
placebo [48]. PPARγ’s are known to bind to and be activated
by EPA, DHA, and DHA metabolites [49–51]a n do m e g a -
3 PUFA supplementation has also been shown to reverse
age-related decreases in the levels of PPARγ in the aged rat
forebrain [41].
There are a number of inﬂammatory events that occur
in the brain as a response to the presence of Aβ. The key
event appears to be the presence of activated microglia in
the vicinity of the Aβ-containing plaques [52]. Microglial
activation results in the sustained production of proinﬂam-
matory cytokines, growth factors, complement molecules,
and adhesion molecules [53]. It has also been demonstrated
that exposure of microglia to β-amyloid ﬁbrils leads to the
production of reactive oxygen species and neurotoxins [54]
and activated microglia generate and release large numbers
of superoxide ions [52], thereby increasing oxidative stress.
The remainder of this paper will focus on this increased
oxidative stress and inﬂammation and the potential role of
omega-3 PUFA.
3. OxidativeStressand LipidPeroxidation
The importance of increased oxidative stress, lipid perox-
idation, and lipid peroxidation products has consistently
been shown in the pathogenesis of AD [4]. For example,
increased lipid peroxidation has been detected in the frontal,
temporal, parietal, and occipital cortices of AD patients
[55]. Moreover, signiﬁcantly increased levels of the lipid
peroxidation products 4-hydroxynonenal and acrolein, are
foundinthehippocampus/parahippocampalgyrus,superior
and middle temporal gyrus, and cerebellum of subjects with
mild cognitive impairment and early AD compared to age-
matched controls [56], suggesting that lipid peroxidation
occurs as an early event in the pathogenesis of AD. This
is consistent with evidence from animal models of AD,
where increased oxidative stress is also found in the APPsw
(Tg2576) transgenic mouse model of AD amyloidosis.
Cerebral cortical and hippocampal homogenates were found
to have higher levels of lipid peroxidation than those from
wild-type mice, and lipid peroxidation preceded amyloid
plaque formation [57].
Isoprostanes are prostaglandin-like compounds formed
in situ by nonenzymatic free radical-catalysed lipid peroxi-
dation [58]. F2-isoprostanes are derived from the omega-6
PUFA, arachidonic acid, F3-isoprostanes from EPA and F4-
isoprostanes,alsocalledneuroprostanes,fromDHA[59–61].
Measurement of isoprostanes provides a sensitive marker of
invivolipidperoxidation[62–64].Measurementscomparing
thelevelofisoprostanesandneuroprostanesbetweenADand
matched controls in diﬀerent regions of postmortem brains
show a PUFA-speciﬁc pattern of lipid peroxidation. There
is an increase in esteriﬁed neuroprostanes in the occipital
and temporal lobes, whereas F2-isoprostanes in these regions
are unchanged [65]. Similar results were found by Reich
and coworkers, in the superior and middle temporal gyri,
hippocampus, inferior parietal lobule, and cerebral cortex
[66]. There were increased levels of neuroprostanes while
F2-isoprostanes levels were unchanged. These results show
a selective pattern of lipid peroxidation occuring in AD,
whereby DHA appears especially vulnerable and arachidonic
acid is unaﬀected.
These results may reﬂect more than simply the regional
distribution of PUFA, since grey matter, where DHA is more
abundant, has a signiﬁcantly greater susceptibility to oxida-
tive stress than white matter [64]. Levels of F2-isoprostanes
and neuroprostanes was measured in the grey and white
matter of brains from rats at intervals between 4 and 100
weeks of age. The level of neuroprostanes were consistently
20-fold greater than F2-isoprostanes, whereas DHA content
was only two-fold greater than arachidonic acid, suggesting
that DHA is especially prone to oxidative stress.
PUFAs are particularly susceptible to lipid peroxidation
and as such are a potential abundant source of destruc-
tive peroxidation products. The in vitro peroxidisability
of unsaturated fatty acids is linearly dependent upon the
number of bis-allylic positions, such that the peroxidisability
of DHA is ﬁve times greater than that of the omega-6
PUFA linoleic acid, which contains only two double bonds
[67]. This increased susceptibility would help to explain the
vulnerability of membrane DHA to lipid peroxidation and
may also suggest that elevating omega-3 PUFA intake in
situations of increased oxidative stress, such as AD, would
further increase production of toxic peroxidation products.
Although some studies have shown increased lipid
peroxidation following dietary supplementation with DHA
and EPA in plasma, liver, and kidney [68–73] others have
shown that EPA and DHA enriched diets do not increase
levels of lipid peroxidation [74, 75]. Indeed, rather than4 International Journal of Alzheimer’s Disease
increasing lipid peroxidation DHA has been shown to be
neuroprotective by actually decreasing lipid peroxidation
in the brain [76–78]. For example, rats being fed a diet
enriched with DHA showed a signiﬁcantly reduced level of
cerebral lipid peroxide compared to controls [78], and the
level of peroxidation was inversely related to the cerebral
DHA/arachidonic acid ratio [77]. Furthermore, Tg2576
transgenic mice being fed a DHA deﬁcient diet have signif-
icantly elevated levels of oxidised proteins compared to the
control group, whereas the levels of oxidised proteins were
signiﬁcantly reduced in a DHA supplemented group [79].
Overall, these results suggest that DHA may function in
an antioxidant role, at least in the brain. Yavin and colleagues
have suggested a number of potential mechanisms for these
observed antioxidant eﬀects [80]. Membrane bound DHA
may act as a trap for reactive oxygen species, DHA may
be able to enhance the activity of endogenous antioxidant
enzymes, or phosphatidylethanolamine plasmalogens con-
taining DHA may contain intrinsic antioxidant properties.
DHA has also been shown to induce antioxidant defences
by enhancing cerebral activities of catalase, glutathione
peroxidase, and levels of glutathione [81]. Furthermore,
workbyGreenandcolleaguessuggeststhatDHAmayreduce
reactive oxygen species production by increasing nitric oxide
production,whichmaydecreasethecellularoxygenpooland
consequently reduce the amount of reactive oxygen species
and generate lipid peroxides [82].
4. FattyAcid Composition
Theincreasedlipidperoxidationandconcomitantdamageto
membrane PUFA have the potential to signiﬁcantly reduce
the brain levels of PUFA and speciﬁcally DHA. However,
a recent review found that low DHA is not consistently
observed in plasma or brain of AD patients [83]. Although
the authors did note wide variability between studies and
suggestedthatitma ybetooearlytodra wan yr eliablec onclu-
sions. They did however report AD to be consistently asso-
ciated with signiﬁcantly lower phosphatidylethanolamine
and phosphatidylcholine concentrations in the frontal cortex
and hippocampus and the DHA content of hippocampal
phosphatidylethanolamine is signiﬁcantly lower compared
to age-matched controls.
DHA is particularly enriched in phosphatidylethanola-
mine [84], and this is therefore an important cellular store
of DHA. Furthermore, in the hippocampal CA1 region of
AD patients unesteriﬁed DHA and neuroprotectin D1 levels
are reported to be about one-half and one-twentieth of those
in age-matched controls, respectively [28]. It may therefore
be hypothesised that although DHA decreases do not appear
widespread or large in magnitude, these selective decreases
in the hippocampus may have profound eﬀects on speciﬁc
cellular pools and the subsequent production of key DHA
metabolites.
5. Inﬂammation
In comparison with nondemented elderly subjects virtu-
ally all the inﬂammatory cytokines and chemokines so
far investigated appear to be upregulated in AD patients,
including IL-1β,I L - 6 ,T N F - α, IL-8, transforming growth
factor-β (TGF-β), and macrophage inﬂammatory protein-
1α (MIP-1α), for reviews see [3, 85]. The most notable
proinﬂammatory cytokines produced by microglial cells, IL-
1α and IL-1β are found throughout the brain of AD patients
at autopsy [86]. IL-1β induces formation of reactive oxygen
species, causing lipid peroxidation, and depletes membrane
PUFA levels [87, 88]. IL-1β also triggers microglial activation
and increases expression of amyloid precursor protein [89,
90].Age-relatedincreasesinIL-1βarecoupledwithincreased
activity of MAPK, c-jun-N-terminal kinases (JNK, a stress
activated MAP kinase), and p38 kinase and enhanced
caspase-3 activity (an eﬀector of apoptosis) [91]. MAP
kinases mediate many speciﬁc cellular responses, including
apoptosis and stress responses.
EPA supplementation has been reported to decrease the
production of proinﬂammatory cytokines in rodents. For
example, EPA reversed the age-related increases in IL-1β
concentration and activation of p38 and caspase-3 [92]. The
EPA supplementation also restored age-related decreases in
arachidonic acid and DHA concentrations and decreased
reactive oxygen species accumulation. It has also recently
been shown that IL-1β reduces acetylcholine release in rats,
which correlates with memory deﬁcits, and EPA supplemen-
tationpreventstheeﬀectsofIL-1β andsigniﬁcantlyimproves
memory [93]. Degeneration of cholinergic neurons is
thought to contribute to cognitive impairments in AD [94].
EPA and DHA are the precursors of a diverse array
of second messengers, called resolvins and docosanoids,
with potent anti-inﬂammatory and proresolving actions [30,
95, 96]. Resolution of inﬂammation has traditionally been
thought of as a passive process; however, recent evidence
suggests that resolution is an active process involving the
biosynthesis of local lipid derived mediators within the
resolution phase, called resolvins [96]. The D class resolvins,
derived from DHA block TNF-α-induced IL-1β transcripts
in brain [95] and resolvin E1 (RvE1), produced from
EPA, reduces IL-12 production via the ChemR23 receptor
[97]. 10,17S-docosatriene, also known as neuroprotectin
D1 is produced from DHA [30] and potently blocks the
generation of both TNF-α and IFN-c by stimulated T cells
[98]. Together, these data suggest that the omega-3 PUFA
metabolites have the potential to decrease inﬂammation by
decreasing inﬂammatory cytokine production.
Most human dietary supplementation studies inves-
tigating the eﬀects of omega-3 PUFA on cytokine pro-
duction have typically examined the eﬀects of high EPA
rather than DHA preparations [99–105]. EPA and DHA
have diﬀering eﬀects on inﬂammatory response and they
should not be considered as having mechanistic equivalence
[106, 107]. Furthermore, EPA and DHA produce distinct
metabolites, and it may be that DHA is the more potent
immunological modulator via production of neuropro-
tectin D1. A recent trial supplemented 174AD patients
with a high DHA preparation (1.7g DHA and 0.6g EPA
or placebo for 6 months) [108]. The DHA/EPA supple-
mented patients had signiﬁcantly reduced IL-1β,a n dI L - 6
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mononuclear cells compared to the placebo group, although
TNF-α, IL-8, IL-10 and granulocyte colony-stimulating
factor were not aﬀected.
The mechanism by which DHA and EPA are able to
attenuate inﬂammatory processes has yet to be elucidated;
however it is likely that these observed eﬀects are mediated
at the level of gene regulation by modifying the actions of
transcription factors, with nuclear factor-kappa B (NF-κB) a
being potential candidate.NF-κB has many diverse functions
in the nervous system and regulates a large number of genes
encoding many inﬂammatory cytokines, such as IL-1β,I L - 6 ,
INF-α, and MCP-1; however, it also regulates anti- and
proapoptotic proteins including Bcl-2, Bcl-xl, Bcl-xs, Bax,
cyclooygenase-2, and inducible nitric oxide synthase [109].
NF-κB activation occurs following a signalling cascade
initiated by external inﬂammatory stimuli and involves the
phosphorylation and subsequent degradation of the IκB
inhibitory subunit, which allows NF-κB translocation to the
nucleus and the subsequent activation of expression of target
genes [109].
The role of NF-κB appears to be determined by cell
type and timing of activation. For example, activation
of NF-κB in neurons associated with amyloid deposits is
currently thought to be neuroprotective, whereas induction
of NF-κB in glia may be neurotoxic. For reviews see [109–
111]. EPA or omega-3 PUFA supplemented media decreases
lipopolysaccharide-induced activation of NF-κBa n dT N F -
α levels in cultured macrophages [112, 113] and mono-
cytes [114], importantly, DHA suppresses IL-6 production
and activation of NF-κB in lipopolysaccharide/interferon-γ
stimulated glial cells [115], suggesting omega-3 PUFAs may
have direct eﬀects on inﬂammatory cytokine production via
eﬀects on the NF-κB signalling pathway. However, their site
of action in this pathway and speciﬁc eﬀects in neurons are
yet to be determined.
6. Conclusions
Although there are strong correlations between low tissue
levels of omega-3 PUFA and increased risk of AD, and low
dietary intakes of omega-3 PUFA and cognitive decline and
AD [116, 117], the results of dietary intervention studies
have so far failed to live up to expectations raised by the
preclinical and epidemiological studies. In the ﬁrst study
to look at the eﬀects of omega-3 PUFA in AD, Yehuda
and colleagues conducted a 4 week double-blind trial
with 100AD patients [118]. The supplemented group
showed improvements in mood, cooperativity, short-term
memory, appetite, sleep, and spatial orientation, whereas no
improvements were seen in the placebo group. A subsequent
pilot study investigated the eﬀects of 500mg EPA given twice
daily for 12 weeks in patients with AD [119]. No diﬀerences
were found and the authors concluded that EPA had no
eﬀects on cognition. A larger study in 174 patients found
that administration of 1.7g of DHA and 0.6g of EPA per day
for 6 months in patients with mild to moderate AD did not
delay the rate of cognitive decline [120], although, positive
eﬀects were observed in a small subgroup of patients with
very mild AD (MMSE >27 points).
Therefore, current evidence appears to indicate that the
beneﬁcial eﬀects of omega-3 PUFAs are more related to
limiting the progression of cognitive decline, as most clinical
trials have so far failed to demonstrate the eﬃcacy of omega-
3PUFAtreatmentaftertheonsetofADsymptoms.However,
itshouldbenotedthatpreclinicalstudieshavefocusedonthe
eﬀects of DHA and its metabolites, whereas clinical studies
have investigated EPA, or may have used insuﬃcient doses
of DHA. In brain tissue, DHA-derived metabolites promote
resolution and protect neural cells from neurodegeneration
[121] and may therefore be the more important omega-
3 PUFA in modulating the secretion of cytokines and
inhibiting neuroinﬂammation and oxidative stress in AD.
Furthermore, recent evidence suggests that the beneﬁcial
eﬀects of omega-3 PUFA on reducing the risk of dementia
and AD may be reduced by the presence of the apolipopro-
tein E ε4( APOE ε4) allele [122–124]. It is hoped that future
clinical studies will help clarify these issues and the relative
roles and utility of DHA and EPA in the treatment of AD.
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